JP2017505779A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505779A5 JP2017505779A5 JP2016549488A JP2016549488A JP2017505779A5 JP 2017505779 A5 JP2017505779 A5 JP 2017505779A5 JP 2016549488 A JP2016549488 A JP 2016549488A JP 2016549488 A JP2016549488 A JP 2016549488A JP 2017505779 A5 JP2017505779 A5 JP 2017505779A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- alkyl
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 37
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 230000004845 protein aggregation Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 9
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 7
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 208000009829 Lewy Body Disease Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- -1 chloro, bromo, methyl Chemical group 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims 2
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 claims 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 claims 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 150000002780 morpholines Chemical class 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims 1
- 150000003852 triazoles Chemical class 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461933246P | 2014-01-29 | 2014-01-29 | |
| US61/933,246 | 2014-01-29 | ||
| US201462078895P | 2014-11-12 | 2014-11-12 | |
| US62/078,895 | 2014-11-12 | ||
| PCT/US2015/013263 WO2015116663A1 (en) | 2014-01-29 | 2015-01-28 | Heteroarly amides as inhibitors of protein aggregation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019104159A Division JP6783900B2 (ja) | 2014-01-29 | 2019-06-04 | タンパク質凝集の阻害剤としてのヘテロアリールアミド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017505779A JP2017505779A (ja) | 2017-02-23 |
| JP2017505779A5 true JP2017505779A5 (enExample) | 2018-02-22 |
| JP6619741B2 JP6619741B2 (ja) | 2019-12-11 |
Family
ID=52484559
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549488A Active JP6619741B2 (ja) | 2014-01-29 | 2015-01-28 | タンパク質凝集の阻害剤としてのヘテロアリールアミド |
| JP2019104159A Active JP6783900B2 (ja) | 2014-01-29 | 2019-06-04 | タンパク質凝集の阻害剤としてのヘテロアリールアミド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019104159A Active JP6783900B2 (ja) | 2014-01-29 | 2019-06-04 | タンパク質凝集の阻害剤としてのヘテロアリールアミド |
Country Status (38)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20161393A1 (es) | 2014-01-29 | 2017-01-08 | Neuropore Therapies Inc | Heteroaril amidas como inhibidores de agregacion de proteina |
| WO2017020010A1 (en) | 2015-07-29 | 2017-02-02 | Neuropore Therapies, Inc. | Bis-heteroaryl derivatives as modulators of protein aggregation |
| CN107625767A (zh) * | 2016-11-25 | 2018-01-26 | 刘淑兰 | 一种治疗慢性盆腔炎的药物 |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| EP3573981B1 (en) * | 2017-01-26 | 2022-03-16 | UCB Biopharma SRL | Alkoxy bis-heteroaryl derivatives as modulators of protein aggregation |
| AU2018212438C1 (en) * | 2017-01-26 | 2021-05-06 | UCB Biopharma SRL | Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation |
| BR112019011932A2 (pt) * | 2017-01-26 | 2019-10-29 | Ucb Biopharma Sprl | derivados de bis-heteroarila como moduladores da agregação de proteína |
| WO2018206778A1 (en) * | 2017-05-12 | 2018-11-15 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma |
| JP2020529432A (ja) | 2017-08-04 | 2020-10-08 | アキシャル バイオセラピューティクス, インク.Axial Biotherapeutics, Inc. | 微生物により誘発されるアミロイドの阻害剤 |
| EP3703730A4 (en) * | 2017-10-31 | 2022-01-12 | Loma Linda University | METHODS OF TREATMENT OF TRAUMATIC BRAIN LESIONS |
| CN112912376A (zh) | 2018-08-20 | 2021-06-04 | 阿尔维纳斯运营股份有限公司 | 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物 |
| EP4458824A1 (en) * | 2021-12-27 | 2024-11-06 | Shanghai Jingxin Biomedical Co., Ltd. | Fused bicyclic heteroaryl amide compound as protein aggregation inhibitor |
| GB202213796D0 (en) * | 2022-09-21 | 2022-11-02 | Wista Lab Ltd | Tau aggregation inhibitors |
| WO2024094731A1 (en) * | 2022-11-02 | 2024-05-10 | Ac Immune Sa | Novel compounds for the diagnosis of tdp-43 proteinopathies |
| WO2024184179A1 (en) | 2023-03-06 | 2024-09-12 | UCB Biopharma SRL | Minzasolmin for use in the treatment of parkinson's disease |
| WO2024184180A1 (en) | 2023-03-06 | 2024-09-12 | UCB Biopharma SRL | Minzasolmin for use in the treatment of parkinson's disease |
| WO2025002040A1 (zh) * | 2023-06-25 | 2025-01-02 | 上海京新生物医药有限公司 | 双环杂芳基酰胺化合物的晶型及盐、制备方法和用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997023202A1 (en) * | 1995-12-22 | 1997-07-03 | STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON | Subtype-selective nmda receptor ligands and the use thereof |
| WO2004048343A1 (en) * | 2002-11-28 | 2004-06-10 | Schering Aktiengesellschaft | Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
| CN101385722A (zh) * | 2003-02-27 | 2009-03-18 | 乔安妮·麦克劳林 | 预防、治疗和诊断蛋白聚集疾病的方法 |
| PT1697371E (pt) * | 2003-12-19 | 2007-08-03 | Bristol Myers Squibb Co | Heterocíclos azabicíclicos como moduladores do receptor de canabinóides |
| KR20070018824A (ko) * | 2003-12-19 | 2007-02-14 | 브리스톨-마이어스 스큅 컴퍼니 | 카나비노이드 수용체 조절제인 아자비사이클릭헤테로사이클 |
| TW200528455A (en) * | 2003-12-19 | 2005-09-01 | Bristol Myers Squibb Co | Azabicyclic heterocycles as cannabinoid receptor modulators |
| JP4242911B2 (ja) * | 2004-08-26 | 2009-03-25 | ファイザー・インク | プロテインキナーゼ阻害薬としてのエナンチオピュアなアミノヘテロアリール化合物 |
| EP1797084A1 (en) * | 2004-09-20 | 2007-06-20 | 4Sc Ag | NOVEL HETEROCYCLIC NF-kB INHIBITORS |
| SE0403119D0 (sv) * | 2004-12-21 | 2004-12-21 | Astrazeneca Ab | Therapeutic agents |
| JP2009505948A (ja) * | 2005-07-11 | 2009-02-12 | デブジェン エヌブイ | キナーゼ阻害剤としてのアミド誘導体 |
| UA97348C2 (en) * | 2005-07-29 | 2012-02-10 | 4Сц Аг | HETEROCYCLIC NF-kB INHIBITORS |
| MX2008011696A (es) * | 2006-03-15 | 2008-11-12 | 4Sc Ag | Inhibidores de nf-kb heterociclicos novedosos. |
| US8362066B2 (en) * | 2006-11-17 | 2013-01-29 | Treventis Corporation | Compounds and methods for treating protein folding disorders |
| WO2008157425A2 (en) * | 2007-06-14 | 2008-12-24 | The Regents Of The University Of California | Compounds for inhibiting protein aggregation, and methods for making and using them |
| WO2010068452A1 (en) * | 2008-11-25 | 2010-06-17 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| GB0910003D0 (en) * | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| CA2776480A1 (en) * | 2009-10-20 | 2011-04-28 | Pfizer Inc. | Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators |
| JP5922031B2 (ja) * | 2009-12-16 | 2016-05-24 | ニューロポア セラピーズ，インコーポレイティド | 化合物 |
| GB201021103D0 (en) | 2010-12-13 | 2011-01-26 | Univ Leuven Kath | New compounds for the treatment of neurodegenerative diseases |
| WO2013134371A1 (en) | 2012-03-06 | 2013-09-12 | Neuropore Therapies, Inc. | Methods and compounds to be used in the treatment of neurodegenerative diseases |
| CA2867175A1 (en) | 2012-03-28 | 2013-10-03 | Neuropore Therapies, Inc. | Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation |
| MX2015000618A (es) * | 2012-07-16 | 2015-04-10 | Neuropore Therapies Inc | Derivados de di- y tri-heteroarilo como inhibidores de la agregacion de proteinas. |
| PE20161393A1 (es) | 2014-01-29 | 2017-01-08 | Neuropore Therapies Inc | Heteroaril amidas como inhibidores de agregacion de proteina |
| WO2017020010A1 (en) | 2015-07-29 | 2017-02-02 | Neuropore Therapies, Inc. | Bis-heteroaryl derivatives as modulators of protein aggregation |
| BR112019011932A2 (pt) | 2017-01-26 | 2019-10-29 | Ucb Biopharma Sprl | derivados de bis-heteroarila como moduladores da agregação de proteína |
| AU2018212438C1 (en) | 2017-01-26 | 2021-05-06 | UCB Biopharma SRL | Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation |
-
2015
- 2015-01-28 PE PE2016001285A patent/PE20161393A1/es unknown
- 2015-01-28 AP AP2016009347A patent/AP2016009347A0/en unknown
- 2015-01-28 BR BR112016017344-9A patent/BR112016017344B1/pt active IP Right Grant
- 2015-01-28 HR HRP20180813TT patent/HRP20180813T1/hr unknown
- 2015-01-28 ES ES15705417.2T patent/ES2675301T3/es active Active
- 2015-01-28 SM SM20200376T patent/SMT202000376T1/it unknown
- 2015-01-28 KR KR1020167023810A patent/KR102383038B1/ko active Active
- 2015-01-28 UA UAA201609003A patent/UA118209C2/uk unknown
- 2015-01-28 PT PT181569294T patent/PT3348556T/pt unknown
- 2015-01-28 CN CN201911278647.XA patent/CN111039939B/zh active Active
- 2015-01-28 HK HK17105014.2A patent/HK1231470A1/zh unknown
- 2015-01-28 SG SG11201606108RA patent/SG11201606108RA/en unknown
- 2015-01-28 SI SI201531297T patent/SI3348556T1/sl unknown
- 2015-01-28 TR TR2018/09440T patent/TR201809440T4/tr unknown
- 2015-01-28 JP JP2016549488A patent/JP6619741B2/ja active Active
- 2015-01-28 PL PL18156929T patent/PL3348556T3/pl unknown
- 2015-01-28 NZ NZ722487A patent/NZ722487A/en unknown
- 2015-01-28 EP EP15705417.2A patent/EP3099684B8/en active Active
- 2015-01-28 MX MX2016009896A patent/MX2016009896A/es active IP Right Grant
- 2015-01-28 ME MEP-2020-148A patent/ME03800B/me unknown
- 2015-01-28 SM SM20180318T patent/SMT201800318T1/it unknown
- 2015-01-28 EP EP18156929.4A patent/EP3348556B1/en active Active
- 2015-01-28 HU HUE15705417A patent/HUE040274T2/hu unknown
- 2015-01-28 MY MYPI2016001401A patent/MY187450A/en unknown
- 2015-01-28 EA EA201691529A patent/EA032374B1/ru unknown
- 2015-01-28 CN CN201580017216.1A patent/CN106132960B/zh active Active
- 2015-01-28 SI SI201530252T patent/SI3099684T1/en unknown
- 2015-01-28 ES ES18156929T patent/ES2808978T3/es active Active
- 2015-01-28 BR BR122018001892-5A patent/BR122018001892B1/pt active IP Right Grant
- 2015-01-28 AU AU2015211119A patent/AU2015211119B2/en active Active
- 2015-01-28 CA CA2937967A patent/CA2937967C/en active Active
- 2015-01-28 WO PCT/US2015/013263 patent/WO2015116663A1/en not_active Ceased
- 2015-01-28 DK DK15705417.2T patent/DK3099684T3/en active
- 2015-01-28 RS RS20200827A patent/RS60547B1/sr unknown
- 2015-01-28 RS RS20180644A patent/RS57533B1/sr unknown
- 2015-01-28 PT PT15705417T patent/PT3099684T/pt unknown
- 2015-01-28 HU HUE18156929A patent/HUE050964T2/hu unknown
- 2015-01-28 LT LTEP18156929.4T patent/LT3348556T/lt unknown
- 2015-01-28 PL PL15705417T patent/PL3099684T3/pl unknown
- 2015-01-28 DK DK18156929.4T patent/DK3348556T3/da active
- 2015-01-28 CR CR20160394A patent/CR20160394A/es unknown
- 2015-01-28 LT LTEP15705417.2T patent/LT3099684T/lt unknown
- 2015-12-29 US US14/983,243 patent/US9738635B2/en active Active
-
2016
- 2016-07-27 IL IL246987A patent/IL246987B/en unknown
- 2016-07-28 PH PH12016501493A patent/PH12016501493B1/en unknown
- 2016-07-28 ZA ZA2016/05246A patent/ZA201605246B/en unknown
- 2016-07-28 CL CL2016001918A patent/CL2016001918A1/es unknown
- 2016-07-28 SA SA516371579A patent/SA516371579B1/ar unknown
- 2016-08-29 EC ECIEPI201670327A patent/ECSP16070327A/es unknown
-
2017
- 2017-08-01 US US15/666,503 patent/US10358443B2/en active Active
-
2018
- 2018-06-15 CY CY20181100630T patent/CY1120348T1/el unknown
-
2019
- 2019-06-04 JP JP2019104159A patent/JP6783900B2/ja active Active
- 2019-06-11 US US16/438,348 patent/US11078196B2/en active Active
-
2020
- 2020-07-14 HR HRP20201107TT patent/HRP20201107T8/hr unknown
- 2020-07-24 CY CY20201100682T patent/CY1123374T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017505779A5 (enExample) | ||
| HRP20201107T1 (hr) | Heteroaril amidi kao inhibitori proteinske agregacije | |
| ZA202006378B (en) | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof | |
| PH12019501707A1 (en) | N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor | |
| WO2021147236A9 (zh) | 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用 | |
| CA2683696A1 (en) | Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity | |
| JP2016518437A5 (enExample) | ||
| JP2013510825A5 (enExample) | ||
| PH12019500615A1 (en) | 5-[2-(PYRIDIN-2-YLAMINO)-1,3-THIAZOL-5-YL]-2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND THEIR USE AS DUAL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE DELTA and GAMMA | |
| JP2015510916A5 (enExample) | ||
| JP2020512981A5 (enExample) | ||
| BR112015016184A2 (pt) | derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| JP2016540811A5 (enExample) | ||
| NZ629453A (en) | Thiazole derivatives as alpha 7 nachr modulators | |
| PH12021551232A1 (en) | Haloallylamine compounds and application thereof | |
| EP4606427A3 (en) | Tricyclic fused heterocyclic pde3/4 dual inhibitor and use thereof | |
| ZA202106097B (en) | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition and uses thereof | |
| JP2016537432A5 (enExample) | ||
| RU2017128880A (ru) | Производные (r)-2-метил-пиперазина в качестве модуляторов cxcr3 рецептора | |
| CN111601788A (zh) | 衣壳蛋白装配抑制剂、其药物组合物和用途 | |
| JP2016507546A5 (enExample) | ||
| JP2011518843A5 (enExample) | ||
| MX2010013978A (es) | Derivados de 5-(4-metanosulfonilfenil)tiazol para el tratamiento de enfermedades inflamatorias agudas y cronicas. | |
| CN114829357A (zh) | 五元杂环氧代羧酸类化合物及其医药用途 | |
| JP2016027024A5 (enExample) |